Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06898476 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Silkworm Pupa Powder Improves Dementia.

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Primary and study completion dates: Dec 31, 2026 to Dec 31, 2027v4
  3. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026
    • Primary endpoints revised (3)
    • Secondary endpoints revised (2)
    • Site contact updated
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 19, 2025 to Apr 10, 2025
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to determine whether silkworm pupa powder is effective in treating Alzheimer's disease. It will also investigate whether silkworm pupa powder can improve the nutritional and frailty status of patients with Dementia. The main questions it aims to answer are: * Will silkworm pupa powder improve the daily living conditions of patients with Alzheimer's disease? * Will silkworm pupa powder improve the nutritional status and frailty of Alzheimer's disease patients? Researchers will compare silkworm pupa powder with a placebo (a similar substance containing 0.5% silkworm pupa powder) to see if silkworm pupa powder can treat Alzheimer's disease. Participants will: * Take silkworm pupa powder or placebo daily for four months; * Visit the clinic for check-ups and tests every four weeks; * Record their symptoms and various physiological indicators.
Trial Details
NCT Number NCT06898476
Lead Sponsor Zhejiang Provincial Tongde Hospital
Collaborators: Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
Conditions
(from sponsor)		 Alzheimer Disease(AD), Sarcopenia, Asthenia
Related terms Alzheimer Disease, Asthenia, Sarcopenia
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov